Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05536388 · ClinicalTrials.gov registry record
Drug Discovery for Parkinson's With Mutations in the GBA Gene
A clinical trial of Healthy and Parkinson Disease, sponsored by New York Stem Cell Foundation Research Institute.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05536388: Recruiting study of Healthy and Parkinson Disease, sponsored by New York Stem Cell Foundation Research Institute.
NCT05536388 is a study of Healthy and Parkinson Disease that is actively recruiting participants, run by New York Stem Cell Foundation Research Institute. The registered enrollment target is 60 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05536388, a study of Healthy and Parkinson Disease, is actively recruiting participants, sponsored by New York Stem Cell Foundation Research Institute.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.
Conditions Studied
Interventions
- OTHER Biological Sample Collection
Study Locations (1)
New York
- The New York Stem Cell Foundation Research Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2025-07-15 |
What NCT05536388 shows while recruiting
NCT05536388 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Biological Sample Collection is the first listed.
NCT05536388 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05536388 about?
NCT05536388 is a clinical study titled "Drug Discovery for Parkinson's With Mutations in the GBA Gene". The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform ge...
What is the current status of trial NCT05536388?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2022-07-15. Estimated completion is 2025-07-15.
What conditions does trial NCT05536388 study?
This clinical trial studies the following conditions: Healthy, Parkinson Disease, Gaucher Disease, GBA Gene Mutation.
What interventions are being tested in trial NCT05536388?
The interventions under investigation include: Biological Sample Collection (OTHER).
Who is sponsoring clinical trial NCT05536388?
This trial is sponsored by New York Stem Cell Foundation Research Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05536388 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05536388's enrollment target sits among peer trials
60 369th of 1090 higher than 689 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI